title: First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.
abstract: Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prognosis patients are 41 and 48%, respectively after standard-dose chemotherapy. We report the experience of the EBMT Solid Tumours Working Party (STWP) with first-line HDCT with hematopoietic progenitor cell support (HPCS) in patients with poor prognosis extragonadal nonseminomatous germ cell tumor (NSGCT). Between 1990 and 2001, 22 extragonadal NSGCT patients (21 M, 1 F), median age 30 years (range 17-52) were treated with first-line HDCT with HPCS. Primary site was mediastinum in 11 patients, retroperitoneum in 10, and unknown in one. The Carbopec regimen, consisting of high doses of carboplatin, etoposide, and cyclophosphamide, was used in most cases (12 patients). No treatment-related deaths occurred. No patient developed myelodysplasia or a secondary leukemia. In total, 17 of 22 patients (77%) achieved complete remission. At a median follow-up of 50 months (range 26-132), 15 patients (68%) are alive disease-free. The survival rates of patients with poor prognosis extragonadal NSGCT treated with first-line HDCT in the EBMT STWP experience appear higher than that expected according to the IGCCCG classification.
authors.affiliation: Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ospedale Civile, Viale Randi 5, 1-48100 Ravenna, Italy. rosti@ra.nettuno.it
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: U
authors.initials: U
authors.lastname: De Giorgi
authors.forename: H
authors.initials: H
authors.lastname: Wandt
authors.forename: B
authors.initials: B
authors.lastname: Lioure
authors.forename: S
authors.initials: S
authors.lastname: Leyvraz
authors.forename: K
authors.initials: K
authors.lastname: Kolbe
authors.forename: G
authors.initials: G
authors.lastname: Papiani
authors.forename: M
authors.initials: M
authors.lastname: Ballardini
authors.forename: A
authors.initials: A
authors.lastname: Kulekci
authors.forename: T
authors.initials: T
authors.lastname: Demirer
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D018237:Germinoma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries; D012074:Remission Induction; D012189:Retrospective Studies; D020379:Risk Adjustment; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents